ArticleOncology letters2017
Apigenin enhances the cisplatin cytotoxic effect through p53-modulated apoptosis.
Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 80 citations in OpenAlex.
- Apigenin as a Multi-Targeted Agent in Gastrointestinal Cancers: A Systems Pharmacology Approach.Advanced pharmaceutical bulletin · 2026Article
- Recent Advancements in Bioactive Natural Products and Nanoparticle-Mediated Drug Delivery in Cancer Therapy.International journal of molecular sciences · 2026Review
- Apigenin combined with cisplatin suppressed the progression of colorectal cancer by targeting the KRT23/Wnt/β-catenin signaling pathway.Discover oncology · 2025Article
- The Anti-Tumor and Bortezomib-Sensitizing Effects of Apigenin in Multiple Myeloma.Current issues in molecular biology · 2025Article
- Apigenin: A Bioflavonoid with a Promising Role in Disease Prevention and Treatment.Biomedicines · 2024Review
- Antimicrobial, Antioxidant and Cytotoxic Effects of Essential Oil, Fatty Acids and Bioactive Compounds ofIndian journal of microbiology · 2024Article
- Apigenin's Modulation of Doxorubicin Efficacy in Breast Cancer.Molecules (Basel, Switzerland) · 2024Article
- Apigenin and its combination with Vorinostat induces apoptotic-mediated cell death in TNBC by modulating the epigenetic and apoptotic regulators and related miRNAs.Scientific reports · 2024Article
- Review
- Enhancing therapy with nano-based delivery systems: exploring the bioactive properties and effects of apigenin.Therapeutic delivery · 2024Review
- Himalayan flora: targeting various molecular pathways in lung cancer.Medical oncology (Northwood, London, England) · 2023Review
- An Update on the Therapeutic Anticancer Potential ofMolecules (Basel, Switzerland) · 2023Review
- The Involvement of Natural Polyphenols in Molecular Mechanisms Inducing Apoptosis in Tumor Cells: A Promising Adjuvant in Cancer Therapy.International journal of molecular sciences · 2023Review
- The Potential Role of Apigenin in Cancer Prevention and Treatment.Molecules (Basel, Switzerland) · 2022Review
- Can dietary flavonoids be useful in the personalized treatment of colorectal cancer?World journal of gastrointestinal oncology · 2022Review
- The effect of apigenin and chemotherapy combination treatments on apoptosis-related genes and proteins in acute leukaemia cell lines.Scientific reports · 2022Article
- Role of Induced Programmed Cell Death in the Chemopreventive Potential of Apigenin.International journal of molecular sciences · 2022Review
- Influence of Olive Oil and Its Components on Breast Cancer: Molecular Mechanisms.Molecules (Basel, Switzerland) · 2022Review
- Chemoprotective and chemosensitizing effects of apigenin on cancer therapy.Cancer cell international · 2021Review
- Apamin-Conjugated Alendronate Sodium Nanocomplex for Management of Pancreatic Cancer.Pharmaceuticals (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidemiological and experimental evidence suggests that dietary flavonoids, including apigenin, have anticancer roles. Apigenin has been reported to elevate p53, a critical molecule in the induction of apoptosis. The present study aimed to investigate whether apigenin, a dietary flavonoid, improves the cytotoxic effect of cisplatin in a cancer cell culture system, and to elucidate the mechanism of this effect. Multiple tumor cell types were treated with apigenin, cisplatin or both drugs. Cell viability was evaluated, and the cytotoxic effect was determined biochemically and microscopically. Treatment with apigenin increased cisplatin-induced DNA damage and the apoptosis of tumor cells in a p53-dependent manner. Apigenin, when used with cisplatin, inhibited cell proliferation and promoted mitogen-activated protein kinase activation and subsequent p53 phosphorylation, leading to p53 accumulation and upregulation of proapoptotic proteins. Cisplatin is one of the most commonly used chemotherapeutic drugs for malignant tumors, but resistance to this drug occurs. The current results therefore demonstrate that dietary flavonoids may diminish the resistance of cancers to cisplatin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.